Educational information only. Not medical advice. SafePeptideUse sells nothing and is not a substitute for a qualified clinician. Talk to a healthcare professional before making any health decision.
← Peptide database

Cerebrolysin

Cognitive & nootropic

Also known as: Cerebrolysin neuropeptide preparation

A neurotrophic mixture of small peptides and amino acids, given by infusion for stroke, dementia, and brain injury.

Safety:This is a biological mixture given by IV or IM in a clinical setting, not a single peptide you mix at home. Large reviews find the evidence mixed, and it is not approved in the US.

2.What it is / mechanism

Cerebrolysin is not a single peptide. It is a mixture of small peptides and free amino acids made from purified pig brain protein. It is meant to act like the brain's own neurotrophic factors, supporting neuron survival and repair. It is used in some countries for stroke recovery, dementia, and traumatic brain injury, given as an intravenous or infusion.s1

3.What the evidence supports

  • Limited human dataMay help cognitive recovery after stroke and in vascular or Alzheimer's dementia.s1

    Some trials, such as CASTA, and meta analyses show benefit, but Cochrane reviews call the evidence for acute stroke insufficient and do not recommend routine use in dementia. The picture is mixed.

  • Limited human dataSupports recovery after traumatic brain injury.s2

    Some positive meta analysis signals, still not definitive.

4.Dosing

Limited human data
Route(s)intravenous, intramuscular
Typical rangeGiven in a clinic as an infusion, commonly 10 to 30 mL per day (up to 50 mL) for courses of 10 to 21 days.
FrequencyDaily during a course, in a clinical setting
Cycle guidance10 to 21 day courses, sometimes repeated every few months.
NotesCerebrolysin comes as a ready made sterile solution in ampoules, so there is nothing to . It is dosed in milliliters and given by a clinician, usually as an IV infusion. This is not a peptide you mix and inject at home.
s1

5.Reconstitution

DiluentNone. It comes as a ready made sterile solution.
ConcentrationNot reconstituted. It is supplied as a solution in ampoules and dosed in milliliters, usually diluted into an IV drip by a clinician.
NotesThere is no home reconstitution step for Cerebrolysin.

General reconstitution technique →

6.Storage & stability

Lyophilized (dry)

TempNot listed
Shelf lifeNot listed
NotesNot applicable. Cerebrolysin is supplied as a solution, not a freeze dried powder.

Reconstituted

TempPer the product label, usually room temperature or refrigerated
Shelf lifeNot listed
NotesStore the ampoules as directed and protect from light. Do not use if the solution is discolored.

General storage & stability guide →

7.Reported side effects

  • SeriousSerious allergic reaction(rare)s1Rare, but seek care for hives, swelling, or trouble breathing.
  • CautionDizziness or feeling warm during the infusion(common)s1More likely if infused too fast. Slowing the rate usually helps.
  • CautionAgitation or restlessness(uncommon)s1

8.Interactions & stacking risks

  • WarningMAO inhibitor antidepressantss1

    The product label advises against combining Cerebrolysin with MAO inhibitors.

9.Contraindications / who should avoid

  • SeriousKnown allergy to Cerebrolysin

    Risk of a serious allergic reaction.

  • WarningSevere kidney impairment or active seizures

    Used with caution or avoided in these settings.

  • SeriousPregnancy or breastfeeding

    No safety data in pregnancy or breastfeeding.

10.COA & purity notes

Common adulterantscounterfeit vials, since a branded product exists, solutions that have degraded or are past date
MislabelingThere is a branded, regulated product in some countries. Because it is a biological made from animal tissue, sterility and source matter, and counterfeits exist.
NotesA biological mixture, not a single peptide. Not approved in the US. Given in clinical settings elsewhere.

How to read a COA →

11.Sources

  1. [s1]Cochrane Database of Systematic Reviews (2020). Cerebrolysin for acute ischaemic stroke (Cochrane systematic review). review link
  2. [s2]PMC (systematic review) (2023). Cerebrolysin in patients with traumatic brain injury: systematic review and meta-analysis. review link

Last reviewed 2026-07-08 · status: reviewed